Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 64fludarabine phosphate 40Peripheral Blood Stem Cell Transplantation 34Vincristine 31Methotrexate 31Etoposide 29Cytarabine 29Dexamethasone 28Doxorubicin 26Whole-Body Irradiation 25Mycophenolic Acid 23Prednisone 22Tacrolimus 21Filgrastim 21Busulfan 19Calcium Dobesilate 18Antilymphocyte Serum 18venetoclax 17nelarabine 17Cyclosporine 17merphos 16Rituximab 14Radiotherapy 14Methylprednisolone 13Bortezomib 13pegaspargase 12dexamethasone acetate 12dexamethasone 21-phosphate 12auricularum 11Melphalan 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × crenigacestat × Clear all
NCT02518113 2019-09-11

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Eli Lilly and Company

Phase 1/2 Completed
36 enrolled 17 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡